(Mtb), the etiologic agent of TB, from TB patients is a complicated process that takes a long time. The excessive immune inflammatory response of the host for a long time causes irreversible organic damage to the lungs and liver. Current antibiotic-based treatment options involve multiple complex drug combinations, often targeting different physiological processes of Mtb. Given the high incidence of post-tuberculosis lung disease, we should also consider the immunomodulatory properties of other drugs when selecting drug combinations.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- inflammatory response
- end stage renal disease
- ejection fraction
- lps induced
- oxidative stress
- newly diagnosed
- chronic kidney disease
- lipopolysaccharide induced
- peritoneal dialysis
- prognostic factors
- risk factors
- emergency department
- signaling pathway
- drug induced
- adverse drug
- toll like receptor
- weight gain
- body mass index
- pi k akt
- cancer therapy
- electronic health record
- human immunodeficiency virus
- patient reported
- antiretroviral therapy